Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03864185Phase 2Completed

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

Role: collaborator

NCT04274257Phase 2Completed

A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis

Role: collaborator

NCT01682473Phase 1Completed

A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies

Role: lead

NCT01280487Phase 1Completed

A Safety Study of Oral ZSTK474 in Patients With Cancer

Role: lead

All 4 trials loaded